Category Archives: Stell Cell Research


Stem cell therapy can help in treating diabetic heart disease – India.com

Karaikal, Feb 28 (PTI) Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge.

Patients suffering from the condition have to undergo lifelong treatment and medications. In this backdrop, advancements in stem cell therapy assume significance, he said.

This is published unedited from the PTI feed.

Antodaya, Humsafar Express to be launched today; Suresh Prabhu to unveil new catering policy for railways today

Uttar Pradesh Assembly elections 2017 LIVE: 57.36% voter turnout recorded till 5 PM in the fifth phase

Oscars 2017: Late Bollywood veteran Om Puri remembered at 89th Academy Awards!

Oscars 2017: Moonlight star Mahershala Ali is now best 'Actor in a Supporting Role'

Oscar Awards 2017 Live: When is Oscars 2017? Where to watch 89th Academy Awards LIVE Streaming & online telecast in India?

Here is the original post:
Stem cell therapy can help in treating diabetic heart disease - India.com

Durham scientists pioneer innovative stem cell research – Palatinate

By Jacob Dykes

In Durham, a pioneering technology has been developed which is providing a solution to fundamental issues in tissue engineering and stem cell biology. The development of new innovative technology enables the advancement of the research and discovery process and scientific thinking as a whole. For example, its hard to conceive of a biomedical sphere untouched by the blessing of PCR or DNA sequencing. Technological advancements not only offer solutions to existing obstacles, they open up new avenues of research into previously inconceivable areas.

With the current levels of excitement in the research of stem cell biology, you could be forgiven for envisaging a utopian medical scenario where a process akin to science-fiction allows us to generate complex tissues in a Petri-dish, ready for transplantation into the damaged organism. The scientific community has speculated that the nature of stem cells, in their ability to self-renew and produce cell types of any lineage will eventually provide medical solutions to some of our most vilified tissue diseases.

Transitioning speculation to reality requires time, basic research and technology development. A novel product known as Alvetex has been developed by Reinnervate, a Durham University spin-out company, which enables a new routine approach to study stem cells and their ability to form tissues in the laboratory. The product unlocks the potential of stem cell differentiation by mimicking the natural three-dimensional (3D) microenvironment cells encounter in the body, enabling the formation of 3D tissue-like structures.

Cell behaviour, in general, is guided by the complex 3D microenvironment in which they reside. Dispersal of cell-cell interactions and architectural contacts across the surface of the cell are essential for regulating gene expression, the genetic mechanism by which cells change their character and behaviour. Recreation of this microenvironment in the laboratory is essential to studying physiologically relevant behaviour, and the differentiation process by which cells form new cell types. Alvetex is a micro-engineered 3D polystyrene scaffold into which cells can be impregnated for cultivation. Cells grow within a 200-micron thick membrane of the 3D material bathed in culture medium. The microenvironment enables cells to form 3D contacts with neighbouring cells, recreating the more natural interactions found in real tissues. Overall, this affects the structure and function of the cells, enabling them to behave more like their native counterparts, which in turn improves predictive accuracy when working with advanced cell culture models.

We can take progenitor cells from the skin of donors and produce human skin We can take cell lines from the intestine and reproduce the absorptive lining of the intestine. We can take neural progenitors and recapitulate 3D neural networks.

Stefan Przyborski is a Professor of Cell Technology at Durham University and the founder of Reinnervate. He gave us an insight into his technologys applications;

We can take progenitor cells from the skin of donors and produce a full-thickness stratified human skin model (see image). We can take cell lines from the intestine and reproduce the absorptive lining of the intestine. We can take neural progenitors and recapitulate 3D neural networks to simulate aspects of nervous system function. Each of these models can be used to advance basic research, and extend our understanding of tissue development, and simulate aspects of disease.

Such technology is underpinned by well established fundamental principles such as how cellular structure is related to function, which hails way back to Da Vinci himself. It is well known that if you get the structure and the anatomy correct than the physiology will start to follow.

Alvetex technology has already been used in research that has led the publication of over 60 research papers in the field of tissue engineering and cancer biology. One particular group used the technology to successfully test drugs to prevent glioblastoma dispersal, an innovative application in brain oncology. Another has developed a 3D skin model to better study the development of metastatic melanoma, a persistently incurable invasive tumour of the skin. US scientists have used Alvetex on the International Space Station to study the formation of bone tissue in microgravity conditions.

The technology promises to be a cost-effective and ethical solution to current obstacles in cell culturing methods, producing better quality data relevant to man and reducing the need for animal models. Alvetex technology has offered a generational contribution to the process of tissue engineering research, yet the founder has higher ambitions;

What I would like to see in the next few decades is the increased complexity of the tissues that stem cells can be used to generate. If you consider the structure of an organ, the complexity, arrangement and structural organisation of those cell populations, it is far from where we are today. Advances in technology at the interface between disciplines leads to new innovative ideas to solve problems and open up new opportunities.

The development of stem cell research is an incremental process. We have to remain cautious given the potential of stem cell therapy to cause tumour formation, highlighting the need for more stringent models and controls. However, the clinical transplantation of cultured stem cells in bone and cornea repair demonstrates their enormous potential. Laboratory experiments have also demonstrated the potential of stem cells to produce kidney, pancreatic, liver, cardiac and muscle cells. It is hoped that continued research using more physiologically relevant technologies will increase the complexity of these tissues in the lab, and the diversity of their application.

Innovative technological advances play an important role in the process of biomedical science. Scientists at Durham are instrumental in the development of such new technologies that enable the process of new discoveries.

Photograph: Prof Stefan Przyborski, Durham University

View post:
Durham scientists pioneer innovative stem cell research - Palatinate

Strongsville man attemps stem cell treatment for MS – WKYC-TV

Strongsville man tries stem cell treatment for MS

Monica Robins, WKYC 12:30 AM. EST February 25, 2017

(Photo: Monica Robins, WKYC)

STRONGSVILLE - Multiple Sclerosis is an unpredictable and often disabling neurological disease affecting more than 2 million people worldwide.

There is no cure, but there is hope.

And it may lie in stem cell research, which is both experimental and controversial.

One Strongsville man is willing to take a chance, in the hopes he'll get back some of what the disease has stolen from him.

To look at him, Gary LaBuda appears to be the picture of health. But when you watch him walk, you realize something isn't quite right.

Four years ago, doctors diagnosed the 43-year-old with multiple sclerosis, or MS. A devastating, degenerating neurological disease.

After a year on MS medication, his world changed in a day.

"Every single symptom you could possibly have hit me and literally stopped me from working," he explains. "That day was the last day of my work."

Some of those symptoms included slurring, constant dizziness and migraines, plus heat fatigue.

His vision and cognitive function was also affected, causing him to lose words.

Gary believes the cause was the medication. "Every single side effect you can get from that medication, I got from that medication," he says. "That was over fifty side effects and I had every single one."

Switching medication and dosage didn't help, so Gary stopped taking it.

He started looking for alternatives including cryotherapy and dry needling for constant muscle spasms and tightness, physical therapy for strength.

But now he's trying an experimental option.

Plastic Surgeon Mark Foglietti and Sports Medicine Doctor Michael Kellis each had a keen interest in stem cell science and decided to offer it to patients. They created the Ohio Stem Cell Treatment Center of Cleveland, an affiliate of the National Cell Surgical Network.

There is a disclaimer on their website, indicating the treatment is not FDA approved and not known to cure any disease or injury. Studies have shown the procedure is safe but it's not covered by insurance.

Gary is paying $8,600 for hope.

"There's no guarantee," he says. "But there's also no risk, so it's not gonna hurt nothing."

The procedure involves using liposuction to remove dormant mesenchymal stem cells in Gary's fat tissue. They are activated, or woken up, by being spun in a centrifuge.

20 MS patients have been treated by Foglietti and Kelils so far. They've seen patients show improvement in the mental fog, then speech is improved, followed by decreased muscle spasms and increased coordination.

The procedure for Gary ends with him receiving his own cells in an IV. He's hoping this is the day a miracle will happen and he is grateful for the chance. He won't know for three months if the treatment has worked.

The doctors say they always emphasize to the patient that this treatment may not work for them, it might work for them, it's hard to know. But it is an opportunity to supply a safe, effective alternative to what's not working in medicine.

( 2017 WKYC)

Follow this link:
Strongsville man attemps stem cell treatment for MS - WKYC-TV

Girl, eight, with rare brain disorder in pioneering UCL stem cell research – Evening Standard

A girl of eight whose rare brain disorder is likely to lead to her death when she is in her teens is taking part in pioneering stem cell research in a bid to save others with same condition.

Lily Harrisss skin cells will first be turned into stem cells and then into brain cells by researchers at University College London as they seek treatments or a cure.

About 100 to 200 cases of BPAN beta-propeller protein-associated neurodegeneration are known worldwide, although this is believed to be an underestimate.

Children often suffer delayed development, sleep problems, epilepsy and lack of speech and their symptoms can be mistaken for other conditions.

Lily, from Luton, was diagnosed when she was five. She has very limited communication skills and uses a wheelchair. She wakes four or five times a night and needs drugs to control seizures.

However, she loves swimming and her father Simon said she has recently began singing on car journeys.

Shes laughed and giggled her way through everything, and shes been through a lot, he said.

Shes a beautiful little girl who can be quite naughty sometimes. Were giving her the best time we can while shes here. We have a beautiful little girl and its just so cruel.

Young people with BPAN develop abnormal muscle tone, symptoms of Parkinsons disease and dementia.

Mr Harriss and his wife Samantha, who work for an airline, know that as Lilys condition progresses she may have difficulty swallowing and require pain management.

Mr Harriss said: Lily can point to things she wants, she uses a little sign language and she can say a few words, like mummy, daddy, hello and goodbye.

Medical research like this for children is just absolutely vital.

We know we wont get a cure for Lily but, as parents, we need to be bigger than that. Other children might benefit through Lily. We are so proud of her.

The UCL study is being funded by 230,000 from childrens charity Action Medical Research and the British Paediatric Neurology Association. Lead researcher Dr Apostolos Papandreou hopes his research will lead to trials of treatments.

He said: The parents Ive met understandably feel devastated at the prospect of their children having a progressive disorder. However, theyre really keen to explore new avenues and participate in research projects.

See more here:
Girl, eight, with rare brain disorder in pioneering UCL stem cell research - Evening Standard

Research on retinal pigment epithelial cells promises new future treatment for glaucoma patients – Science Daily

Research on retinal pigment epithelial cells promises new future treatment for glaucoma patients
Science Daily
Scientific research builds its own momentum as one discovery triggers another, building an ongoing wave of unexpected possibilities. In the world of glaucoma, such a surge began when advances in stem cell research opened doors experts had never ...

Go here to read the rest:
Research on retinal pigment epithelial cells promises new future treatment for glaucoma patients - Science Daily

Angels’ Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery – CBS Local


CBS Local
Angels' Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery
CBS Local
This, combined with new advances in stem cell technology, gave Richards the option to avoid going under the knife and instead undergo stem cell treatment. This and much more on the topic of stem cell research and its role in baseball was revealed in a ...

and more »

Originally posted here:
Angels' Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery - CBS Local

AgriScience Fair projects range from stem cell research to measuring gluten sensitivities in dogs and humans – Reading Eagle

Every year at the Pennsylvania Farm Show, members of the FFA gather to compete in the AgriScience Fair.

The contest requires that students conduct research and present their findings in ways that help them prepare for their future and develop research skills.

Many students use the program as a part of their Supervised Agricultural Experience, a crucial part of agricultural education that goes along with classroom instruction and FFA involvement. In past years, members of the Conrad Weiser FFA Chapter have excelled in this event at state and national levels, with students placing first, second or third in the nation in a variety of divisions.

Each year brings new students and new opportunities to the AgriScience Fair, which introduced a new division structure for the 2017 competition.

This year, more than 150 students from around the state competed in the AgriScience Fair. Of these, 45 were from the Conrad Weiser FFA, many of them freshmen and first-time competitors.

Students from the Conrad Weiser FFA Chapter were honored for their research in categories ranging from food systems to social systems to environmental and natural resource systems, many of them placing first.

Among those placing first was Adam Zappacosta, a freshman who studied chicken feed as a part of his Animal Systems project. Adam worked on a team with Will Savoy, another freshman, to complete his project and said the AgriScience Fair will benefit him in the future.

Another team representing Conrad Weiser was Rini Kaneria and Lacie Pichler, who studied the effects of antibiotics on the function of murine mesenchymal cells.

Their studies earned them second place in their Animal Systems division.

Kaneria, a junior at Conrad Weiser, was positive about her experiences, even though her team may not be able to go to the national competition.

"I feel as if I learned so much just from doing this project," she said.

Cate Palumbo and Rachel Kesselring, two freshmen, based their project on a topic studied in class, Integrated Pest Management, or IPM.

When asked about the origins of their research, Kesselring said, "This idea was the beginning of our project."

Palumbo added, "The idea for our project happened gradually. We originally liked the idea of doing a project with essential oils, and after some research, we found that essential oils help with pest control."

That line of research led to their project about the effects of peppermint on the muscle tissue and digestive tracts of tobacco hornworms. It earned them first place in the Environmental and Natural Resource Systems division.

"AgriScience showed me that all the scientists who conduct big experiments started somewhere," Palumbo said,

Earning Best in Show and first in his division of Animal Systems with his project about gluten sensitivities was Joseph Gresoi, junior and two-time competitor at the AgriScience Fair.

He started work on his project in 2015, and with the help of some of the science teachers at Conrad Weiser, he shaped his research not only into a science project, but also into countless opportunities.

"The development of this project has been one of the best educational experiences of my life," Gresoi said.

Through his work, he has "had the opportunity to collaborate with scientists across multiple disciplines and learned more than he could have ever hoped for."

Conrad Weiser "Aggies" were full of positive things to say about the FFA AgriScience Fair.

Many are looking into applying for the national competition, which will take place later this year. Among them are Palumbo and Kesselring, Zappacosta and Savoy, and individual competitor Gresoi, who wants to take his project "as far as he can."

As for the rest of the Conrad Weiser FFA Chapter, they cannot wait to see where these scientists go in the future and what wonderful things the future, and their research, bring.

Visit link:
AgriScience Fair projects range from stem cell research to measuring gluten sensitivities in dogs and humans - Reading Eagle

How baseball players are trying stem cells to avoid Tommy John – Yahoo Sports

TEMPE, Ariz. On the day he hoped would save his elbow, Garrett Richards laid face down on a table with his back exposed. A doctor guided a needle into the iliac crest of his pelvic bone and began to extract bone marrow. Richards was wide awake, the blessing of local anesthesia saving him from physical pain but not the anxiety that crept into his head: Is this really going to work?

Within a few minutes, the harvested marrow was hurried to a centrifuge, spun to separate the good stuff, mixed into a slurry of platelet-rich plasma and readied to inject into Richards damaged right elbow. Rather than the standard tear across his ulnar collateral ligament, Richards ran lengthwise along the middle of his UCL, a rare manifestation of an increasingly commonplace injury that almost always ends with Tommy John surgery. Not in this case. While he could have chosen that route, he wanted to explore first the efficacy of the aforementioned good stuff: stem cells.

Today, Garrett Richards is darting 98-mph fastballs again. I feel as good as I ever have throwing a baseball, he said Monday from Tempe Diablo Stadium, where the Los Angeles Angels, perhaps the most Tommy John-addled team in baseball, expect to break camp with Richards as their opening day starter. The 28-year-old is the latest player to turn to orthobiologics, the class of treatments that includes stem cells and PRP, in hopes of healing an injury. While clinical studies have shown great success with those who use orthobiologics, they are not yet a panacea for the pervasive elbow injuries in baseball for two reasons: They work only on partial ligament tears, like Richards, and medical studies have yet to validate their efficacy independent of other treatments run concurrently.

The lack of knowledge as to how orthobiologics work inside the body while the proteins in stem cells and platelets are believed to regrow damaged tissue, doctors have yet to isolate best practices for particular injuries speaks to the difficulties in true medical advances. Still, the desire of Richards and others to avoid surgery lends orthobiologics enough credence to warrant further studies.

I truly think this kind of treatment has significant potential, said Dr. Neal ElAttrache, a longtime orthopedic surgeon at the Kerlan-Jobe clinic in Los Angeles who introduced orthobiologics to Major League Baseball when he injected PRP into the elbow of Dodgers reliever Takashi Saito in 2008. Theres no question biologics are here to stay and biologic manipulation is the frontier of treatment in what were doing. The problem, as I see it, is that the marketing and clinical use has far exceeded the science behind it.

Translation: Once the use of PRP and stem cells found traction in the media, pro athletes and weekend warriors alike sought their use, even if the success stories skewed anecdotal. Bartolo Colon resurrected his career after a stem cell injection in 2010 and is still pitching today at 43. Others did so without the fanfare or publicity. Richards faced a choice after being diagnosed with a partially torn UCL last May: Undergo Tommy John surgery and, at earliest, return following the 2017 All-Star break or follow the advice of Dr. Steve Yoon, a partner of ElAttraches at Kerlan-Jobe, and try to salvage the ligament with stem cells.

Science, bro, Richards said. Im a believer now.

Two weeks before Richards began his treatment, teammate Andrew Heaney had looked to avoid Tommy John via stem cells. Richards figured theyd rehab together every step of the way and be back in time for the fall instructional league. Then at the end of June, a scan showed Heaneys elbow wasnt healing, and he would need reconstructive surgery. Already Tyler Skaggs had taken nearly two years to return from his 2014 surgery, and six weeks after Heaneys, starter Nick Tropeano went down. Like Heaney, he is expected to miss the 2017 season.

It made Richards recovery that much more imperative. His first checkup, six weeks in, showed regrowth in the torn area via ultrasound. By August, he started throwing, and come October, when instructional league was in full bloom, so too was Richards. He didnt hesitate to pump his fastball and rip off one of his spin-heavy breaking balls. As far as pure, raw stuff goes, few in baseball can match Richards.

Read More

He was convinced science was working, bro, though the skepticism about orthobiologics generally remains, and understandably so, in the medical community. In May 2013, a paper published in the American Journal of Sports Medicine found 30 of 34 overhand throwers with partial UCL tears who used PRP had returned to their previous level of competition. This was reason for celebration. If a player could avoid the 14-month-plus recovery from the surgery, better for him as well as the team.

Another study arrived in 2016 that didnt cast doubt on the value of orthobiologics so much as offer a different avenue: rest. The 28 players used everything from electrical stimulation, ultrasound, laser therapy, massage and other soft-tissue work. And when paired with rest, their return to previous level came in at 84 percent. It was almost exactly as effective as PRP.

This reinforced ElAttraches concern: Neither of those studies had a control group against which to measure, so the numbers, while impressive, could not isolate what helped and what didnt. This chicken-or-egg question struck ElAttrache just the same when Saito returned and went on to pitch five seasons.

Maybe it was the injection, ElAttrache said. Or maybe it was that we shut him down and let him heal.

Garrett Richards is darting 98-mph fastballs again after turning to orthobiologics. (Getty Images)

He doesnt know, and thats an important distinction as orthobiologics grows exponentially. In 2004, voters in California pledged to provide $3 billion for stem-cell research and create the California Institute of Regenerative Medicine. It remains a benefactor for an industry trying to find its place in the United States.

Across the world, stem cells have far greater potency. U.S. law prevents doctors from manipulating the cells in any way. They are extracted and put back into patients bodies as is. In Switzerland, for example, doctors will harvest stem cells, manipulate them to promote greater healing capacity and then inject them. At least one star pitcher this offseason sought a stem cell injection in the United States, according to sources, while another veteran traveled halfway across the world to Zurich, seeking the comparative lack of regulations just as Peyton Manning did in 2011 to help heal a neck injury that eventually needed surgery.

The future of orthobiologics domestically doesnt end with the FDA loosening rules on stem cell usage. Doctors see significant promise in stem cells from a babys umbilical cord or a mothers placenta, both of which can be frozen. Already theyre capable of harvesting stem cells from old patients and engineering the cells into an immature state. The possibilities going forward are endless.

For right now, theyre going to play themselves out in Anaheim. The danger zone for re-injury after using orthobiologics tends to fall between April and June, though Richards cant imagine falling prey again. In addition to the 13-week break from throwing he took over the summer, Richards spent 10 more weeks in the offseason letting it heal further.

During his down time, Richards studied his own delivery to find even the slightest inefficiencies. He had three numbers in mind. The first was 85. Thats the percent at which he said hell throw his fastball, though because of improved mechanics he expects it wont hinder his velocity. The second is 100. Thats the pitch limit the Angels will foist on Richards, and hes not one to fight. The third is 200. Thats the number of innings Richards wants to pitch this season. He did it in 2015 and sees no reason he cant again.

If he can throw 85 percent, keep his pitch count below 100 and get those 200 innings, it will play publicly as another validation of orthobiologics. Just the same, if Richards elbow gives out eventually, his association with stem cells could perhaps give those considering it pause. Richards pays no mind to this. He just wants to be great.

So much so, in fact, that its going to cost him. Inside the Angels clubhouse, a chart, labeled 1 through 13, is taped to the side of a locker. Its a list of shame with the price buying lunch for the entire team. Players, coaches, P.R. directors, even manager Mike Scioscia are on there. Next to No. 6, it read: G. Rich Ace. He had made the mistake of saying aloud what he believed to be true: that hes the ace of the Angels.

Fulfilling that depends on plenty of things, none as important as his elbow, and Richards knows that. Hell do everything he can to take care of it, to nurture it, to fight against its natural gift of velocity that puts him at such risk. To make sure that next time hes on a table in the doctors office, its not with his elbow opened up and another season lost.

More on Yahoo Sports: Tom Bradys missing jersey is worth a small fortune Bob Huggins says he fell to his knees because his defibrillator activated Kings GM Vlade Divac says he turned down abetter deal for DeMarcus Cousins Yoenis Cespedes is back with his amazing cars

See more here:
How baseball players are trying stem cells to avoid Tommy John - Yahoo Sports

Multiple sclerosis: Stem cell transplantation may halt disease progression – Medical News Today

New research provides further evidence of autologous hematopoietic stem cell transplantation as an effective treatment for multiple sclerosis, after finding the procedure halted disease progression for 5 years in almost half of patients.

Lead study author Dr. Paolo Muraro, of the Department of Medicine at Imperial College London in the United Kingdom, and colleagues recently reported their findings in JAMA Neurology.

The results come just a fortnight after another study revealed the success of a similar treatment in a small group of patients with relapsing-remitting multiple sclerosis (RRMS).

However, Dr. Muraro and team warn that further trials are needed to determine the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT), after a small number of patients died within 100 days of treatment.

In AHSCT, a patient's own stem cells are harvested. The patient is then subject to high-dose chemotherapy to eliminate any diseased cells.

Next, the harvested stem cells are returned to the patient's bloodstream, with the aim of restarting normal blood cell production. In simple terms, AHSCT "resets" the immune system.

"We previously knew this treatment reboots or resets the immune system - and that it carried risks - but we didn't know how long the benefits lasted," notes Dr. Muraro.

For their study, the researchers assessed data from 25 treatment centers across 13 countries, identifying 281 patients with multiple sclerosis (MS) who underwent AHSCT between 1995-2006. Of these patients, 78 percent had a progressive form of MS.

Using the Expanded Disability Status Scale (EDSS), the team evaluated patients' progression-free survival at 5 years after treatment and any improvements in MS symptoms.

An EDSS score of zero represents no disability, seven represents the use of a wheelchair, while 10 represents death from MS. At the beginning of the study, patients had an average EDSS score of 6.5.

Overall, the researchers found that 46 percent of patients experienced no disease progression in the 5 years after treatment.

Patients with RRMS - characterized by inflammatory attacks, or "flare-ups," followed by periods of remission - had the best outcomes, with 73 percent experiencing no worsening of symptoms in the 5 years after AHSCT.

Additionally, patients experienced small improvements in MS symptoms after AHSCT. Patients with progressive MS saw their EDSS score rise by 0.14 a year after treatment, while patients with RRMS experienced a 0.76 increase in their EDSS score.

Patients with a younger age, few immunotherapies prior to AHSCT, and a lower EDSS score at study baseline also showed better outcomes with AHSCT.

While these findings show promise for the use of AHSCT for patients with MS, the team notes that there were eight deaths in the 100 days after AHSCT, which were thought to have been treatment related.

AHSCT involves aggressive chemotherapy, which can severely weaken the immune system and increase susceptibility to infection.

"In this study, which is the largest long-term follow-up study of this procedure, we've shown we can 'freeze' a patient's disease - and stop it from becoming worse, for up to 5 years.

However, we must take into account that the treatment carries a small risk of death, and this is a disease that is not immediately life-threatening."

Dr. Paolo Muraro

Dr. Muraro notes that, importantly, this study did not include a group of MS patients who did not receive treatment, further highlighting the need for more studies assessing the safety and efficacy of AHSCT.

"We urgently need more effective treatments for this devastating condition, and so a large randomized controlled trial of this treatment should be the next step," he adds.

Read about a study that links vitamin D level at birth to the risk of MS.

Here is the original post:
Multiple sclerosis: Stem cell transplantation may halt disease progression - Medical News Today

Local stem cell researcher Sally Temple appears on Dr. Oz – Albany Times Union

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Local stem cell researcher to appear on Dr. Oz today

Sally Temple has a plea for people considering stem cell therapy to cope with a chronic illness or life-threatening disease: Don't. Not yet.

Temple, co-founder of the Neural Stem Cell Institute in Rensselaer and president of the International Society for Stem Cell Research, has spent her career studying stem cells. Her pre-taped appearance on "The Dr. Oz Show" airs Tuesday, Feb. 14, where she talks about the difference between stem cell research and what she calls the "snake oil" promises of clinics that haven't been approved by the FDA but promise miracle cures for scourges like Alzheimer's and Parkinson's diseases.

Stem cells hold promise for treatment because they are the foundation from which all parts of the human body grow.

There are more than 500 clinics in the country offering unproven therapies, including some in New York state and a lot in Florida. "We know it's going on all around the world," Temple said.

Patients lured by false promises spend a lot of money. Temple said people have taken out second mortgages to cover the costs. But they are also at medical risk, Temple said, because injecting stem cells even the patient's own cells can have unpredictable results.

On TV

The Dr. Oz Show airs at 2 p.m. weekdays on NewsChannel 13 WNYT. Learn more about stem cell research at http://neuralsci.org.

"We're now hearing of people getting dreadful outcomes, tumors and blindness," she said.

It's because, without FDA approval and the long process of testing a new drug, there's no way to know for sure what's in the syringe, Temple said. "It may sound good to take stem cells from your own fat and inject them into your eye, but injecting stem cells that were good at making fat into another part of the body where they were never supposed to be can be disastrous."

Dr. Mehmet Oz said he chose this subject because there are stem cell clinics using the potential of legitimate research to take advantage of patients desperate for help.

"These physicians are violating not only the trust of their patients but also the law and hopefully our show will push the FDA to use its authority to shut them down," Oz said.

Temple said she was impressed by how informed Oz was during the taping for the show in New York City last month, and said it was clear the researchers and producers on the show had done their homework. Montel Williams, a former show host himself, also appeared on the segment. Williams suffers from multiple sclerosis and said he's been approached by clinics who want his celebrity endorsement.

"He was fully aware of lack of research and knew that when you dig for scientific rationale, it's not there," Temple said. "True stem cell therapy is coming, but we have to go through the proper channels and know it's safe."

Continue reading here:
Local stem cell researcher Sally Temple appears on Dr. Oz - Albany Times Union